Dose Response to Recombinant Factor VIIa When Administered for Bleed

Phase 1

Completed

• Conditions: Congenital Bleeding Disorder; Healthy

• Registration Number: NCT00104455
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-06
• Primary Completion: 2004-11
• Study Completion: 2004-11
• Study First Submitted: 2005-02-28
• Study First Submitted QC: 2005-02-28
• Study First Posted: 2005-03-01
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-11
• Last Update Posted: 2017-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 64

Inclusion Criteria

• Ages Eligible for Study: 18 Years - 60 Years

Exclusion Criteria

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Dose Response to Recombinant Factor VIIa

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇺🇸 Overland Park, Kansas, United States